Compare Adaptive Biotechnologies Corp (ADPT) vs 3M Company (MMM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs 3M Company — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while 3M Company trades at $156.16 (market cap $82.41B). The key difference: 3M Company is far larger — about 24.7× Adaptive Biotechnologies Corp's market cap, and 3M Company pays a 1.97% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MMM | |
|---|---|---|
Market Cap | $3.33B | $82.41B |
Sector | Health | Industrials |
52-Week High | $22.37 | $174.61 |
52-Week Low | $10.24 | $141.10 |
Enterprise Value | $3.19B | $90.82B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MMM trades at $158.00, down 1.52% today, with a bullish technical signal driven by moving averages. The company reported three consecutive quarterly EPS beats, with Q2 2026 results expected on July 21, 2026. Strong profitability metrics include a 72.14% ROE and 11.14% net margin, though revenue has declined from 2022 peaks. Recent news highlights partnerships with Airbus and an AI tool launch, supporting operational momentum.
Outlook is mixed: analyst consensus is a Hold with a $148.75 price target below current levels, citing limited AI exposure. Risks include volatile cash flows and high debt. Upside depends on execution of growth initiatives and margin improvement. The stock offers a dividend yield with the next payment on June 12, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
